Loading clinical trials...
Loading clinical trials...
A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to the IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions.
Conditions
Interventions
Luspatercept
Placebo
Locations
74
United States
Stanford Cancer Center
Stanford, California, United States
Yale University School of Medicine
New Haven, Connecticut, United States
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Emory University Hospital
Atlanta, Georgia, United States
Ochsner Medical Institutions
New Orleans, Louisiana, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
Start Date
February 9, 2016
Primary Completion Date
June 18, 2019
Completion Date
November 26, 2020
Last Updated
December 17, 2021
NCT07270978
NCT05292664
NCT06499285
NCT04953910
NCT04953897
NCT05350748
Lead Sponsor
Celgene
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions